2014 ESC/EACTS Guidelines on myocardial revascularization
Myocardial revascularization has been subject to more randomized clinical trials (RCTs) than almost any other intervention. In order to inform the current Guidelines, this Task Force performed a systematic review of all RCTs performed since 1980, comparing head-to-head the different revascularization strategies—including CABG, balloon angioplasty, and PCI with bare-metal stents (BMS) or with various US Food and Drug Administration-approved drug-eluting stents (DES)—against medical treatment as well as different revascularization strategies, and retrieved 100 RCTs involving 93 553 patients with 262 090 patient-years of follow-up.
Formulation of the best possible revascularization approach, also taking into consideration the social and cultural context, will often require interaction between cardiologists and cardiac surgeons, referring physicians, or other specialists as appropriate. Patients need help with taking informed decisions about their treatment and the most valuable advice will probably be provided to them by the ‘Heart Team’.
Recognizing the importance of the interaction between cardiologists and cardiac surgeons, the leadership of both the ESC and the EACTS has given this Joint Task Force, along with their respective Guideline Committees, and the reviewers of this document the mission to draft balanced, patient-centred, evidencedriven practice guidelines on myocardial revascularization.
Guidelines er godkendt af DCS 8. januar 2015. Hvor der er kommentarer, afvigende dansk tradition samt forslag til forbedringer, er bemærkningerne knyttet til et nummer og en sidehenvisning.